AGTR1 and Parkinson disease: Regarding PD, studies in different animal models have revealed the role of RAS dysregulation in dopaminergic degeneration and neuroinflammation [25-27], and recent studies in humans have shown that high levels AT1 gene expression identify the most vulnerable human dopaminergic neurons [28-30], and that treatment with AT1 blockers decreases the risk of PD development [31-33].